Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2013 by Massachusetts General Hospital.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Ralph Weissleder, MD, Massachusetts General Hospital Identifier:
First received: June 10, 2009
Last updated: March 19, 2013
Last verified: March 2013
The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic agent(Feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastases in people who have pancreatic cancer and are scheduled for surgical resection.

Condition Intervention Phase
Pancreatic Cancer
Drug: Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • To determine the sensitivity and specificity of high resolution magnetic resonance imaging with lymphotrophic superparamagnetic nanoparticles to identify small and otherwise undetectable lymph node metastases. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • To compare disease-free survival and overall survival intervals for patients whose pre-operative imaging and surgical resection pathology showed no evidence of nodal metastases. [ Time Frame: 3 years ]

Estimated Enrollment: 100
Study Start Date: July 2008
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Superparamagnetic Iron Oxide Magnetic Resonance Imaging
    Three MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
    Other Names:
    • SPIO MRI
    • USPIO
    • Feruoxytol
Detailed Description:
  • On the first day, study participants will undergo 2 MRI examinations. A scan will be done prior to administration of the contrast agent (Feraheme) and then a second scan immediately after administration. On the second day, study participants will be asked to return for a third MRI.
  • All MRI scans will be done at Massachusetts General Hospital.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally resectable pancreatic mass present on one or more pre-operative imaging modalities
  • Must demonstrate no evidence of distant metastases as assessed by chest/abdomen/pelvis CT scan
  • Deemed eligible for resection with curative intent by a treating surgeon who is listed as an investigator on this study
  • 18 years of age or older
  • No uncontrolled serious medical or psychiatric illness
  • Women of childbearing potential must not be pregnant or lactating

Exclusion Criteria:

  • Known allergy to iron or dextran
  • Pregnant or lactating
  • Counter-indication to MRI, such as the presence of metallic prostheses or implanted metal device
  • Sickle cell disease or hemoglobinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00920023

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Ralph Weissleder, MD, PhD Massachussetts General Hospital
  More Information

Responsible Party: Ralph Weissleder, MD, Professor of Radiology, Massachusetts General Hospital Identifier: NCT00920023     History of Changes
Other Study ID Numbers: 08-085
Study First Received: June 10, 2009
Last Updated: March 19, 2013

Keywords provided by Massachusetts General Hospital:

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Ferric Compounds
Trace Elements
Growth Substances
Physiological Effects of Drugs
Plasma Substitutes
Blood Substitutes
Hematinics processed this record on April 28, 2017